Astellas Pharma receives $75 million upfront from MSN under an amended mirabegron (Myrbetriq) licensing agreement, with additional prepaid per-unit fees in the U.S.
Written By: Pharmacally Medical News Desk
Astellas Pharma Inc. has announced an amendment to its existing settlement and licensing agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. (collectively referred to as MSN), concerning the overactive bladder treatment Myrbetriq (generic name: mirabegron).
Under the revised terms, MSN has exercised an option to modify the prior agreement and has made an upfront payment of $75 million to Astellas. In addition to this payment, Astellas will receive prepaid per-unit licensing fees tied to mirabegron tablets marketed and sold by MSN in the United States.
The agreement represents a continuation of Astellas’ strategy to manage lifecycle and market access for Myrbetriq, a beta-3 adrenergic agonist indicated for the treatment of overactive bladder. The licensing structure allows MSN to participate in the U.S. market while providing Astellas with immediate and ongoing financial returns.
Astellas stated that the financial impact of this amended agreement will be incorporated into its forecast for the fiscal year ending March 31, 2027. The company plans to disclose this updated outlook on April 27, 2026.
Astellas Pharma Inc. has recently entered multiple settlement and licensing agreements related to Myrbetriq (mirabegron) in the United States. Earlier in 2026, the company resolved patent litigation with Lupin Limited and Zydus Lifesciences, securing a combined $210 million comprising litigation settlements and upfront license fees, along with prepaid per-unit royalties on generic sales.
These agreements concluded ongoing disputes and enabled the generic manufacturers to continue marketing mirabegron in the U.S. market while providing Astellas with both immediate and recurring revenue streams.
Reference
Astellas Amends Settlement and License Agreement with MSN regarding Myrbetriq®